Xspray Pharma Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Per Andersson
Chief executive officer
SEK 3.7m
Total compensation
CEO salary percentage | 70.5% |
CEO tenure | 19yrs |
CEO ownership | 0.5% |
Management average tenure | 1.3yrs |
Board average tenure | 5.7yrs |
Recent management updates
Recent updates
We Think Xspray Pharma (STO:XSPRAY) Needs To Drive Business Growth Carefully
Feb 25We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate
May 11We Think Xspray Pharma (STO:XSPRAY) Can Afford To Drive Business Growth
Feb 01We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate
Oct 26We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate
Jun 20We're Hopeful That Xspray Pharma (STO:XSPRAY) Will Use Its Cash Wisely
Mar 19Do Institutions Own Xspray Pharma AB (publ) (STO:XSPRAY) Shares?
Feb 12Here's Why We're Watching Xspray Pharma's (STO:XSPRAY) Cash Burn Situation
Dec 04CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2024 | n/a | n/a | -SEK 258m |
Jun 30 2024 | n/a | n/a | -SEK 215m |
Mar 31 2024 | n/a | n/a | -SEK 213m |
Dec 31 2023 | SEK 4m | SEK 3m | -SEK 180m |
Sep 30 2023 | n/a | n/a | -SEK 180m |
Jun 30 2023 | n/a | n/a | -SEK 170m |
Mar 31 2023 | n/a | n/a | -SEK 148m |
Dec 31 2022 | SEK 4m | SEK 2m | -SEK 132m |
Sep 30 2022 | n/a | n/a | -SEK 128m |
Jun 30 2022 | n/a | n/a | -SEK 114m |
Mar 31 2022 | n/a | n/a | -SEK 102m |
Dec 31 2021 | SEK 3m | SEK 2m | -SEK 97m |
Sep 30 2021 | n/a | n/a | -SEK 60m |
Jun 30 2021 | n/a | n/a | -SEK 57m |
Mar 31 2021 | n/a | n/a | -SEK 56m |
Dec 31 2020 | SEK 3m | SEK 2m | -SEK 52m |
Sep 30 2020 | n/a | n/a | -SEK 56m |
Jun 30 2020 | n/a | n/a | -SEK 55m |
Mar 31 2020 | n/a | n/a | -SEK 49m |
Dec 31 2019 | SEK 3m | SEK 2m | -SEK 46m |
Sep 30 2019 | n/a | n/a | -SEK 41m |
Jun 30 2019 | n/a | n/a | -SEK 34m |
Mar 31 2019 | n/a | n/a | -SEK 30m |
Dec 31 2018 | SEK 2m | SEK 2m | -SEK 23m |
Compensation vs Market: Per's total compensation ($USD337.10K) is above average for companies of similar size in the Swedish market ($USD230.11K).
Compensation vs Earnings: Per's compensation has increased whilst the company is unprofitable.
CEO
Per Andersson (57 yo)
19yrs
Tenure
SEK 3,743,000
Compensation
Dr. Per Andersson Ph.D. has been the Chief Executive Officer of Xspray Pharma AB (publ) since 2006. Dr. Andersson serves as the Chief Executive Officer of Xspray Microparticles AB. Dr. Andersson joined XSp...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chief Executive Officer | 19yrs | SEK 3.74m | 0.52% SEK 8.3m | |
Co-Founder and Science Director | no data | no data | no data | |
Chief Financial Officer | less than a year | no data | no data | |
Chief Operating Officer | less than a year | no data | 0.0049% SEK 77.5k | |
Senior Vice President of Research & Development | 7yrs | no data | 0.0081% SEK 129.0k | |
Chief Commercial Officer | 1.3yrs | no data | no data | |
Senior Vice President of Regulatory Affairs | less than a year | no data | 0.0040% SEK 64.5k | |
Senior Vice President of Intellectual Property | 7yrs | no data | 0.081% SEK 1.3m |
1.3yrs
Average Tenure
56yo
Average Age
Experienced Management: XSPRAY's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Independent Director | 10yrs | SEK 323.00k | 0.083% SEK 1.3m | |
Independent Director | 10yrs | SEK 270.00k | no data | |
Chairman | 3.7yrs | SEK 510.00k | 1.55% SEK 24.8m | |
Independent Director | 8yrs | SEK 253.00k | no data | |
Independent Director | 5.7yrs | SEK 270.00k | 0.013% SEK 202.3k | |
Director | 3.7yrs | SEK 253.00k | 2.27% SEK 36.2m | |
Independent Director | 2.7yrs | SEK 218.00k | 0.027% SEK 430.1k |
5.7yrs
Average Tenure
66yo
Average Age
Experienced Board: XSPRAY's board of directors are considered experienced (5.7 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/06 11:26 |
End of Day Share Price | 2025/01/03 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Xspray Pharma AB (publ) is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Dan Akschuti | Pareto Securities |
Filip Einarsson | Redeye |